About Parabilis Medicines
Parabilis Medicines is a publicly listed company based in Cambridge (United States) founded in 2016. Advances innovative peptide therapeutics for cancer and critical diseases treatment. It operates on a B2B model. Parabilis Medicines has raised $628 million across 3 funding rounds from investors including RA Capital, Fidelity Investments and Janus Henderson Investors. Its website parabilismed.com draws about 28 thousand monthly visits. Parabilis Medicines offers products and services including Helicon Peptide Platform and Peptide Therapeutics Programs. Its focus areas include Biotechnology, R&D Platforms, Ultra-tunable Peptides and Therapeutics. Its competitors include IGM Biosciences, Promis Diagnostics and EVQLV; 2 of its 3 listed competitors have raised funding.
Company details
Parabilis Medicines is a biotechnology company that focuses on creating ultra-tunable peptide therapeutics using their Helicon platform. They target severe diseases like cancer through advanced RD and collaborations. Based in Cambridge, MA, they aim to deliver life-changing outcomes for patients by tackling previously unsolvable problems in healthcare.
- Headquarters Cambridge, United States
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website parabilismed.com
- Social LinkedIn
- Legal Name Parabilis Medicines, Inc.
- Total Equity Funding$628M (USD)
in 3 rounds
- Latest Funding Round$305M (USD), Series F
Jan 2026
- InvestorsRA Capital
& 23 more
Products & Services of Parabilis Medicines
Parabilis Medicines offers a comprehensive portfolio of products and services, including Helicon Peptide Platform and Peptide Therapeutics Programs.
Platform for developing ultra-tunable peptides targeting severe diseases.
Programs advancing medicines for cancer and critical health needs.
Funding Insights of Parabilis Medicines
Parabilis Medicines has successfully raised a total of $628M across 3 strategic funding rounds. The most recent funding activity was a Series F round of $305 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $628M
- Total Rounds 3
- Last Round Series F — $305M
- First Round $178M
(Nov 2022)
- Investors Count 24
All 3 funding rounds of Parabilis Medicines with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $305M | Series F | – | RA Capital Management, Fidelity Investments | |
| Mar 2024 | $145M | Series E | – | Nextech Invest | |
| Nov 2022 | $178M | Series D | – | Arch Venture Partners, Fidelity Investments | – |
24 investors in total: 24 institutional.
Investors in Parabilis Medicines
Parabilis Medicines has secured backing from 24 investors, including institutional and venture fund investors. Prominent investors backing the company include RA Capital, Fidelity Investments and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| janushenderson.com | ||||
| frazierls.com | ||||
| soleuscapital.com | ||||
| nextechinvest.com | ||||
| rockspringscapital.com | ||||
| generalcatalyst.com | ||||
| mwam.com | ||||
| samsaracap.com | ||||
| archventure.com | ||||
| gv.com |
Investor details for Parabilis Medicines
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Parabilis Medicines
48 people are tracked at Parabilis Medicines (28 in leadership, 20 in team).
| Name | Role | Group |
|---|---|---|
Alex Hird | Vice President, Medicinal Chemistry Design | Leadership |
Mark Ator | Associate Vice President, Discovery DMPK | Leadership |
Judy Zdanowicz | Vice President, Quality | Leadership |
Mathai Mammen, M.D., Ph.D. | CEO, President and Chairman | Leadership |
Greg Miller | Chief Business Officer | Leadership |
Sandra Smith | Vice President, People | Leadership |
Markus Haeberlein | Executive Vice President, Discovery Science | Leadership |
Chris Martin | Vice President, Manufacturing | Leadership |
Brandon Allgood | Chief Data Science Officer | Leadership |
Rohin Mhatre | Chief Technical Operations Officer | Leadership |
John Mcgee | Scientific Co-founder And Senior Vice President, Platform Technology | Leadership |
Kristen Stants | Chief People Officer | Leadership |
Donovan Chin | Vice President, Computational Drug Discovery | Leadership |
Teresa Jurgensen | Executive Vice President, General Counsel | Leadership |
Thomas Kotarakos | Executive Vice President, Finance | Leadership |
Karthik Sriram | Vice President, Financial Planning & Analysis | Leadership |
Steve Macdonald | Vice President, Corporate Controller | Leadership |
Amanda Garofalo | Vice President, Clinical Operations | Leadership |
Marie Nguyen | Senior Vice President, Head Of Clinical Development | Leadership |
Richa Poddar | Vice President, New Product Planning | Leadership |
28 more people are available in the full profile.
Complete people profiles for Parabilis Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Parabilis Medicines
Parabilis Medicines is a publicly listed company on the NASDAQ with ticker symbol PBLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Jun 2026
- Listed onNASDAQ: PBLS
- Listed entityParabilis Medicines, Inc.
- Exchange sectorHealth technology
- ISINUS6989551014
- Share price$26.85 (-7.25% on the day) · 2026-10-13
- Market capitalisation$3.32B
- Volume (last session)1,187,838
Timeline of Parabilis Medicines
4 dated milestones of Parabilis Medicines across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Parabilis Medicines is founded.
- Funding First funding round of $178.0M.
- Funding Latest funding round, Series F, of $305.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Parabilis Medicines
Parabilis Medicines has 3 listed competitors in our database, 2 of them funded. They include IGM Biosciences, Promis Diagnostics and EVQLV.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| igmbio.com | 2010 | Mountain View, United States | $102.67M | 181 | Antibodies for cancer and infectious disease treatments are developed. | |
| promisdx.com | 2019 | Pasadena, United States | $10.8M | 9 | Non-invasive diagnostics for colorectal cancer screening are developed. | |
| evqlv.com | 2019 | New York, United States | AI-based immunotherapies for cancer and immune diseases are developed. |
Detailed competitors of Parabilis Medicines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Parabilis Medicines
The website of Parabilis Medicines (parabilismed.com) receives about 27.7K visits a month.
- Monthly visits27.7K
▲ 42.3% vs previous month
Websites whose visitors overlap most with Parabilis Medicines. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| parabilis.com | 100% | 2.5K | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Parabilis Medicines (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Parabilis Medicines
Parabilis Medicines was founded in 2016 and raised its 1st funding round 6 years after it was founded.
Parabilis Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Parabilis Medicines is a funded company, having raised a total of $628M across 3 funding rounds to date. The company's 1st funding round was a Series D of $178M, raised on Nov 2022.
Parabilis Medicines is a biotechnology company that focuses on creating ultra-tunable peptide therapeutics using their Helicon platform. They target severe diseases like cancer through advanced RD and collaborations. Based in Cambridge, MA, they aim to deliver life-changing outcomes for patients by tackling previously unsolvable problems in healthcare.
Parabilis Medicines's top competitors include IGM Biosciences, Promis Diagnostics and EVQLV.
Parabilis Medicines offers Helicon Peptide Platform and Peptide Therapeutics Programs.
Yes, Parabilis Medicines is publicly traded on NASDAQ under the ticker symbol PBLS.
Parabilis Medicines has 24 investors. Key investors include RA Capital, Fidelity Investments, Janus Henderson Investors, Frazier Life Sciences, and Soleus Capital.